Duffy Sean P. sold $249K of OMDA

Duffy Sean P. (Chief Executive Officer) sold 12,944 shares of Omada Health, Inc. (OMDA) at $19.22 ($0.25M total) on 2026-11-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Duffy Sean P.
Published Nov 6, 2026, 9:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
medium confidence
Mentioned
$OMDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The disclosed sale is the first public report of this transaction, providing new data for investors monitoring insider activity.

02

Market read

A modest insider sale with limited market impact; primarily of interest to shareholders tracking insider activity.

03

What to watch

The CEO's holdings remain substantial, and the sale follows a pre‑arranged plan, reducing interpretive weight.

Relevance 3/10Novelty 2/10Timing: post‑market 2026‑11‑04

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged sales, often viewed as neutral.

Company-level read

Ticker impact

$OMDANeutralMedium confidence
Context

CEO Sean P. Duffy sold 12,944 shares for $248,730 via a 10b5-1 plan, reducing his stake to 382,594 shares.

Expected impact

potential slight downward pressure as the market prices the insider sell.

Evidence & confidence

A sub‑$250K sale by the CEO is a routine 10b5‑1 transaction; impact is limited but could prompt short‑term sell‑side interest.

Market effects

Minimal effect on digital health sector; no broader industry catalyst.

None

Low

Counterpoint

The sale could be a strategic rebalancing rather than a negative signal.

Key entities

  • Omada Health, Inc.

    Digital health platform listed on Nasdaq under ticker OMDA.

  • Sean P. Duffy

    Chief Executive Officer of Omada Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.